The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.

Disclosures: Marc L Miller, MD Nothing to disclose. Ira N Targoff, MD Consultant/Advisory Boards: Oklahoma Medical Research Foundation Clinical Immunology Laboratory (myositis antibody testing). Jeremy M Shefner, MD, PhD Nothing to disclose. Monica P Ramirez, MD, MPH Employee of UpToDate, Inc.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

Conflict of interest policy

All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Jul 2014. | This topic last updated: Apr 01, 2014.

INTRODUCTION — Rhabdomyolysis is a syndrome characterized by muscle necrosis and the release of intracellular muscle constituents into the circulation. Creatine kinase (CK) levels are typically markedly elevated, and muscle pain and myoglobinuria may be present. The severity of illness ranges from asymptomatic elevations in serum muscle enzymes to life-threatening disease associated with extreme enzyme elevations, electrolyte imbalances, and acute kidney injury.

The causes of rhabdomyolysis will be reviewed here. The clinical manifestations and diagnosis of rhabdomyolysis; the clinical features and diagnosis of acute kidney injury due to rhabdomyolysis; the management of patients with rhabdomyolysis, including methods to prevent acute kidney injury and related metabolic complications; and the prevention and management of acute compartment syndrome are discussed in detail separately. (See "Clinical manifestations and diagnosis of rhabdomyolysis" and "Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)" and "Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)" and "Crush-related acute kidney injury (acute renal failure)" and "Acute compartment syndrome of the extremities".)

PATHOPHYSIOLOGY — The clinical manifestations and complications of rhabdomyolysis result from muscle cell death, which may be triggered by any of a variety of initiating events. The final common pathway for injury is an increase in intracellular free ionized cytoplasmic and mitochondrial calcium. This may be caused by depletion of adenosine triphosphate (ATP), the cellular source of energy, and/or by direct injury and rupture of the plasma membrane [1,2]. The latter pathway of injury also results in ATP depletion.

The increased intracellular calcium leads to activation of proteases, increased skeletal muscle cell contractility, mitochondrial dysfunction, and the production of reactive oxygen species, resulting in skeletal muscle cell death [1]. ATP depletion causes dysfunction of the Na/K-ATPase and Ca2+ATPase pumps that are essential to maintaining integrity of the myocyte. ATP depletion leads to myocyte injury and the release of intracellular muscle constituents, including creatine kinase (CK) and other muscle enzymes, myoglobin, and various electrolytes.

CAUSES — There are multiple potential causes of rhabdomyolysis [3-6]; these can be broadly divided into three categories (table 1):

Traumatic or muscle compression (eg, crush syndrome or prolonged immobilization)

Nontraumatic exertional (eg, marked exertion in untrained individuals, hyperthermia, or metabolic myopathies)

Nontraumatic nonexertional (eg, drugs or toxins, infections, or electrolyte disorders)

The specific cause is frequently evident from the history or from the immediate circumstances preceding the disorder, such as crush injury, a comatose or postictal state, postoperative surgical trauma, or extraordinary physical exertion. In other cases, however, the precipitant may not be as immediately evident but is identified through a careful history and physical and laboratory evaluation [4,5,7]. The specific causes within each of the three major categories are discussed in detail in the sections below.

The relative frequency of the different etiologies among patients with rhabdomyolysis has been reported in several large series of hospitalized patients [3,4,8]. In a study that included 2371 patients with rhabdomyolysis, the most frequently associated clinical conditions included trauma (26 percent), immobilization (18 percent), sepsis (10 percent), vascular surgery (8 percent) and cardiac surgery (6 percent) [8]. In another series of 475 patients, the most common causes were exogenous toxins (46 percent), including alcohol and illicit drugs (34 percent) and medical drugs (11 percent) [4]. Up to 60 percent of patients had more than one etiologic factor. Underlying myopathy or muscle metabolic defects were seen in 10 percent of the cases, in which there was a higher rate of recurrence and only one etiologic factor. No cause was identified in 7 percent of patients. Differences in the reported frequencies and the causes of rhabdomyolysis between these studies are likely related to differences in case ascertainment. (See 'Drugs' below.)

Another series with more than 50 patients focused on patients with infectious causes [9].

Trauma or muscle compression — Trauma or muscle compression is a common cause of rhabdomyolysis and can be seen in the following settings:

A crush syndrome in victims of multiple traumata, particularly individuals trapped in cars after crashes or in collapsed buildings from earthquakes [10-13]. Many of these patients also experience a compartment syndrome. (See "Crush-related acute kidney injury (acute renal failure)".)

Individuals struggling against restraints, torture victims, or abused children [14,15].

Immobilization due to coma of any cause or in conscious individuals forced to lie in one position for hours, such as elderly hip fracture victims [16,17].

Surgical procedures in which there is either prolonged muscle compression due to positioning during a long procedure [13,18,19], or vascular occlusion because of tourniquet use in orthopedic or vascular reconstruction procedures [13,20].

Acute lower extremity compartment syndrome, with tibial fractures being the most common cause. (See "Acute compartment syndrome of the extremities", section on 'Epidemiology and risk factors'.)

High-voltage electrical injury (eg, from lightning or high-voltage power supplies) or extensive third-degree burns, causing direct myofibrillar injury [2,21]. (See "Environmental and weapon-related electrical injuries".)

Nontraumatic exertional rhabdomyolysis — Rhabdomyolysis occurs in individuals with normal muscles when the energy supply to muscle is insufficient to meet demands. Examples include extreme exertion or exertion under conditions in which muscle oxygenation is impaired, including metabolic myopathies.

Subclinical myoglobinemia, myoglobinuria, and elevation in serum creatine kinase (CK) are common following physical exertion. As an example, myoglobinemia was found in 25 of 44 participants (57 percent) in an ultra-marathon race of 99 kilometers [22]. The serum CK rose 16-fold from pre-race levels to a mean of 2060 international units/L. Myoglobin was detected in the urine of five individuals, but acute kidney injury did not occur. In a second study, 39 percent of 337 military recruits developed myoglobinemia during the first six days of basic training, but none had pigmenturia or reported muscle symptoms [23].

Massive rhabdomyolysis may arise with marked physical exertion, particularly when one of more of the following risk factors is present:

The individual is physically untrained.

Exertion occurs in extremely hot, humid conditions, which may lead to exertional heat stroke [24,25]. (See "Severe nonexertional hyperthermia (classic heat stroke) in adults".)

Normal heat loss through sweating is impaired, as with the use of anticholinergic medications or heavy football equipment [25,26]. (See "Severe nonexertional hyperthermia (classic heat stroke) in adults".)

Sickle cell trait occurs in an individual who exercises at high altitude, a setting in which the decreased partial pressure of oxygen causes erythrocyte sickling with subsequent vascular occlusion and muscle ischemia [27,28]. (See "Sickle cell trait", section on 'Risk for sudden death and athletic participation'.)

Hypokalemia caused by potassium loss from sweating occurs [29,30]. The role of potassium in the regulation of skeletal muscle blood flow appears to be important in the pathogenesis in this setting [31]. During exercise, there is normally an appropriate increase in muscle perfusion to meet enhanced energy demands. This hyperemic response is mediated in part by the release of potassium from skeletal muscle cells. The ensuing local elevation in the potassium concentration causes vasodilation, which enhances regional blood flow [31,32]. However, the cellular release of potassium is impaired by potassium depletion. As a result, there is a lesser increase in blood flow, possibly resulting in cramps, ischemic necrosis, and rhabdomyolysis [31]. Hypokalemia-induced impairment in muscle metabolism also may contribute to muscle dysfunction [30].

Rhabdomyolysis can also occur in trained individuals following physical exertion in the absence of these risk factors [22,33].

In addition, pathologic hyperkinetic states can lead to rhabdomyolysis in individuals with normal muscles [3,34]. Examples include:

Grand mal seizures

Delirium tremens

Psychotic agitation

Amphetamine overdose

Metabolic myopathies — Rhabdomyolysis may develop in patients with abnormal muscle, such as individuals with inherited disorders of glycogenolysis, glycolysis, or lipid metabolism (table 2). These disorders are discussed in detail separately. (See "Causes of metabolic myopathies" and "Overview of inherited disorders of glucose and glycogen metabolism".)

The metabolic myopathies represent a very small percentage of cases of rhabdomyolysis overall but are relatively common causes among patients with recurrent episodes of rhabdomyolysis after exertion [35,36]. In a series of 77 patients evaluated for "idiopathic" myoglobinuria in whom muscle biopsies were performed, specific enzyme deficiencies were identified in 36 (47 percent) [36]. Carnitine palmitoyltransferase deficiency was the most common disorder, occurring in 17 of the 36 patients, followed by muscle phosphorylase deficiency (McArdle disease) in 10. (See "Causes of metabolic myopathies", section on 'Fatty acid transport defects' and "Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)".)

The precise mechanism of muscle necrosis in the metabolic myopathies has not yet been established, but it is likely that insufficient energy production in exercising muscle leads to depletion of adenosine triphosphate (ATP) and creatine phosphate. The maintenance of muscle cell integrity is thereby compromised [37]. (See "Approach to the metabolic myopathies", section on 'Myoglobinuria and rhabdomyolysis' and "Energy metabolism in muscle" and 'Pathophysiology' above.)

Postexertional rhabdomyolysis has also been described in individuals with mitochondrial myopathies due to defects in respiratory chain enzymes [38].

Thermal extremes and dysregulation — Rhabdomyolysis may occur with hyperthermia associated with heat stroke (see 'Nontraumatic exertional rhabdomyolysis' above). Other causes of rhabdomyolysis in the setting of temperature dysregulation or thermal extremes include:

Malignant hyperthermia – Rhabdomyolysis is considered a later perioperative manifestation of malignant hyperthermia. Susceptibility is usually due to an inherited abnormality in the ryanodine receptor that causes the unregulated passage of calcium from the sarcoplasmic reticulum into the intracellular space. The most common trigger is the use of inhalation anesthetics. The persistent elevation of calcium causes sustained muscle contraction and results in ATP depletion, which causes hyperkalemia and rhabdomyolysis. (See "Susceptibility to malignant hyperthermia: Evaluation and management" and "Malignant hyperthermia: Clinical diagnosis and management of acute crisis".)

Neuroleptic malignant syndrome – The neuroleptic malignant syndrome is a disorder in which high fever (with or without generalized muscle contraction or tremor) develops after exposure to neuroleptic drugs and anti-Parkinsonian drugs. Rhabdomyolysis has been reported [39]. (See "Neuroleptic malignant syndrome".)

Near drowning/hypothermia – Rhabdomyolysis with myoglobinuric acute renal failure can occur after prolonged immersion [40]. The mechanism of rhabdomyolysis in this setting may involve hypothermia with muscle injury from marked vasoconstriction or from excessive shivering and/or generalized hypoxia. (See "Drowning (submersion injuries)".)

Nonexertional and nontraumatic rhabdomyolysis — Nonexertional and nontraumatic causes of rhabdomyolysis include drugs and toxins, infections, electrolyte abnormalities, endocrinopathies, inflammatory myopathies, and others [2,4-6].

Drugs — A large number of prescription drugs and drugs of abuse can cause rhabdomyolysis [5]. In addition to alcohol, other drugs of abuse that have been implicated as causes include heroin, cocaine, amphetamines, methadone, and D-lysergic acid diethylamide (LSD). In one large series, the prescription drugs most commonly responsible were antipsychotics, followed by statins, selective serotonin reuptake inhibitors, zidovudine, colchicine, lithium, antihistamines, and several others [4].

The illicit and prescribed agents cause rhabdomyolysis through several different mechanisms [41,42]:

Coma induced by alcohol, opioid overdose, or other central nervous system (CNS) depressants leads to immobilization and ischemic compression of muscle.

Some drugs, including statins and colchicine, are direct myotoxins. In addition, statins can increase the risk of rhabdomyolysis in patients with other predisposing conditions, such as hypothyroidism or an inflammatory myopathy [43-45]. (See "Statin myopathy".)

Drug-induced agitation states, drug-induced seizures, dystonic reactions, and cocaine-induced hyperthermia are associated with excess muscle energy demands. (See "Drug-induced myopathies", section on 'Cocaine'.)

Drug-drug interactions may be responsible for rhabdomyolysis in some individuals. The nature of the interactions varies. As an example, some drugs interfere with the clearance of statins and lead to elevated plasma levels; offending agents include macrolide antibiotics (eg, erythromycin and clarithromycin), cyclosporine, gemfibrozil, and some protease inhibitors used in the treatment of HIV infection. (See "Drug-induced myopathies" and "Statin myopathy".)

In some individuals exposed to drugs, multiple mechanisms may contribute to muscle damage; as an example, rhabdomyolysis with alcoholic binges may result from a combination of hypokalemia, hypophosphatemia, coma, agitation, and direct muscle toxicity.

Dietary supplements used for weight loss or enhanced physical performance, which typically contain multiple ingredients, may lead to rhabdomyolysis, possibly as a result of metabolic stress [46,47]. In one report, nutritional supplements used in strength training caused rhabdomyolysis in otherwise healthy individuals [46]. Nutritional supplements containing ephedra, creatine, and large doses of caffeine have been implicated, but these findings have also been reported in patients using supplements lacking these compounds [47].

Patients undergoing isolated limb perfusion for locally recurrent melanoma may develop rhabdomyolysis as a complication of therapy [48,49]. The degree of injury is influenced by the specific drug administered and other factors, possibly including ischemia and hyperthermia. (See "Cutaneous melanoma: Management of local recurrence", section on 'Isolated limb perfusion'.)

Toxins — Rhabdomyolysis may result from exposures to toxins other than medications [5]. These include:

Metabolic poisons, such as carbon monoxide, which lead to insufficient muscle energy production. (See "Carbon monoxide poisoning".)

Snake venoms, which occur from certain snake bites and are most often reported from Asia, Africa, and South America [50,51].

Insect venoms, including wasp and bee stings [5,52,53].

Mushroom poisoning [54-57]. (See "Clinical manifestations and evaluation of mushroom poisoning", section on 'Delayed rhabdomyolysis'.)

An unidentified toxin found in certain types of fish [58-61]. The development of rhabdomyolysis within 24 hours of ingesting fish is referred to as Haff disease.

Infections — Rhabdomyolysis has been associated with a variety of infections, both viral and bacterial [9,62-64].

Acute viral infections associated with rhabdomyolysis include influenza A and B, Coxsackievirus, Epstein-Barr, herpes simplex, parainfluenza, adenovirus, echovirus, human immunodeficiency virus, and cytomegalovirus [62-64]. (See "Viral myositis", section on 'Viral myositis with rhabdomyolysis' and "Muscle disease in HIV-infected patients".)

The mechanism of muscle damage due to viral infections has not been established, as the presence of virus in affected muscle has been difficult to demonstrate consistently.

Other infections associated with rhabdomyolysis include:

Mycoplasma pneumoniae infection [65-67]. (See "Mycoplasma pneumoniae infection in adults", section on 'Other'.)

Bacterial pyomyositis [68]. (See "Pyomyositis".)

Bacterial infections with a variety of microbial organisms, including Legionella, tularemia, Streptococcus and Salmonella, E. coli, leptospirosis, Coxiella burnetii (Q fever), and staphylococcal infection [5,9].

In patients with septicemia without direct muscle infection, muscle damage may be caused by a toxin, or from associated fever, rigors, and dehydration [69,70]. Toxic shock syndrome, most commonly caused by circulating streptococcal or staphylococcal exotoxins, may also result in rhabdomyolysis [71,72]. (See "Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome" and "Staphylococcal toxic shock syndrome".)

Human granulocytic anaplasmosis (ehrlichiosis) [73].

Falciparum malaria [74].

Electrolyte disorders — Rhabdomyolysis has been associated with a variety of electrolyte disorders, particularly hypokalemia [75,76] and hypophosphatemia [77,78]. The latter association is most often seen in alcoholic patients and those receiving hyperalimentation without phosphate supplementation [77]. Cases associated with hyperosmolality due to diabetic ketoacidosis or nonketotic hyperglycemia have also been described, and hypophosphatemia may contribute to the risk of rhabdomyolysis in some of these patients [79-81]. (See "Clinical manifestations and treatment of hypokalemia", section on 'Severe muscle weakness or rhabdomyolysis' and "Signs and symptoms of hypophosphatemia", section on 'Skeletal and smooth muscle' and "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Phosphate depletion'.)

Potassium release from muscle cells during exercise normally mediates vasodilation and the appropriately increased blood flow to muscles. Decreased potassium release due to profound hypokalemia (serum potassium less than 2.5 mEq/L) may promote the development of rhabdomyolysis by decreasing blood flow to muscles in response to exertion.

In both hypokalemic and hypophosphatemic rhabdomyolysis, the serum potassium and phosphate levels may underestimate or mask the underlying total body depletion because of the release of these electrolytes from intracellular stores due to the myonecrosis [77].

Other electrolyte disorders have been occasionally associated with rhabdomyolysis. These include hypocalcemia [82]; hyponatremia, mostly due to primary polydipsia [83,84]; and hypernatremia [85,86].

Endocrine disorders — Several endocrine disorders, including diabetes and thyroid diseases, have been associated with rhabdomyolysis, sometimes in combination with other causes. As noted in the previous section, both diabetic ketoacidosis and nonketotic hyperglycemia have been associated with rhabdomyolysis due at least in part to phosphate depletion and other electrolyte imbalances associated with this condition [79-81].

Hypothyroidism is frequently accompanied by myalgias and mild to moderate serum CK elevations. In addition, overt rhabdomyolysis has been described, and concurrent statin therapy may be a risk factor. (See "Hypothyroid myopathy", section on 'Rhabdomyolysis'.)

Rhabdomyolysis has also been infrequently described in several other endocrine disorders. These include hyperthyroidism [87] and pheochromocytoma [88].

Inflammatory myopathies — Rhabdomyolysis has only rarely been described in patients with the inflammatory myopathies, dermatomyositis and polymyositis [89-91]. (See "Clinical manifestations of dermatomyositis and polymyositis in adults".)

Miscellaneous — Rhabdomyolysis is associated with a number of other conditions in occasional patients:

Status asthmaticus, in which muscle injury may be due to respiratory muscle overexertion and/or generalized muscle hypoxia [92].

The administration of non-depolarizing muscle blocking agents to critically ill intensive care unit patients who require mechanical ventilation. A hypothesis is that muscle was "primed" for such injury by the underlying disease state, the administration of high-dose glucocorticoids, or the presence of an additional factor related to the critical illness [93]. (See "Use of neuromuscular blocking medications in critically ill patients".)

The "capillary leak syndrome," a rare condition in which there are sudden, recurrent episodes of markedly increased capillary permeability, causing shifts of fluid from the intravascular to interstitial compartments. This shift leads to marked edema, limb swelling and possible compartment syndrome, hypovolemia, hypotension, and, in some cases, rhabdomyolysis [94,95]. (See "Idiopathic systemic capillary leak syndrome".)

Abrupt withdrawal of the gamma-aminobutyric acid (GABA) agonist baclofen, particularly if given intrathecally, which can lead to severe muscle spasticity and muscle necrosis [96,97].

SUMMARY AND RECOMMENDATIONS

The clinical manifestations and complications of rhabdomyolysis result from muscle cell death, with the release of intracellular muscle constituents into the circulation. (See 'Introduction' above and 'Pathophysiology' above.)

The multiple potential causes of rhabdomyolysis can be broadly divided into three categories (table 1) (see 'Causes' above):

Traumatic or muscle compression (see 'Trauma or muscle compression' above)

Nontraumatic exertional (see 'Nontraumatic exertional rhabdomyolysis' above and 'Metabolic myopathies' above and 'Thermal extremes and dysregulation' above)

Nontraumatic nonexertional (see 'Nonexertional and nontraumatic rhabdomyolysis' above and 'Drugs' above and 'Infections' above and 'Electrolyte disorders' above and 'Endocrine disorders' above)

The most common clinical conditions associated with rhabdomyolysis include trauma, immobilization, sepsis, and vascular and cardiac surgeries. Other common causes of rhabdomyolysis include overexertion, and drugs and toxins such as lipid-lowering agents, alcohol, and cocaine. The majority of patients have more than one etiologic factor, and less than 10 percent have no identifiable cause. Rhabdomyolysis rarely occurs in association with an inflammatory myopathy. (See 'Causes' above and 'Inflammatory myopathies' above.)

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur J Intern Med 2007; 18:90.
  2. Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med 2009; 67:272.
  3. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore) 1982; 61:141.
  4. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84:377.
  5. Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Crit Care 2005; 9:158.
  6. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361:62.
  7. Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve 2002; 25:332.
  8. McMahon GM, Zeng X, Waikar SS. A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Intern Med 2013; 173:1821.
  9. Blanco JR, Zabalza M, Salcedo J, et al. Rhabdomyolysis of infectious and noninfectious causes. South Med J 2002; 95:542.
  10. Bywaters EG, Beall D. Crush Injuries with Impairment of Renal Function. Br Med J 1941; 1:427.
  11. Vanholder R, Sever MS, Erek E, Lameire N. Acute renal failure related to the crush syndrome: towards an era of seismo-nephrology? Nephrol Dial Transplant 2000; 15:1517.
  12. Sever MS, Erek E, Vanholder R, et al. The Marmara earthquake: epidemiological analysis of the victims with nephrological problems. Kidney Int 2001; 60:1114.
  13. Slater MS, Mullins RJ. Rhabdomyolysis and myoglobinuric renal failure in trauma and surgical patients: a review. J Am Coll Surg 1998; 186:693.
  14. Malik GH, Sirwal IA, Reshi AR, et al. Acute renal failure following physical torture. Nephron 1993; 63:434.
  15. Schwengel D, Ludwig S. Rhabdomyolysis and myoglobinuria as manifestations of child abuse. Pediatr Emerg Care 1985; 1:194.
  16. Penn AS, Rowland LP, Fraser DW. Drugs, coma, and myoglobinuria. Arch Neurol 1972; 26:336.
  17. Szewczyk D, Ovadia P, Abdullah F, Rabinovici R. Pressure-induced rhabdomyolysis and acute renal failure. J Trauma 1998; 44:384.
  18. Lachiewicz PF, Latimer HA. Rhabdomyolysis following total hip arthroplasty. J Bone Joint Surg Br 1991; 73:576.
  19. Biswas S, Gnanasekaran I, Ivatury RR, et al. Exaggerated lithotomy position-related rhabdomyolysis. Am Surg 1997; 63:361.
  20. Adiseshiah M, Round JM, Jones DA. Reperfusion injury in skeletal muscle: a prospective study in patients with acute limb ischaemia and claudicants treated by revascularization. Br J Surg 1992; 79:1026.
  21. Brumback RA, Feeback DL, Leech RW. Rhabdomyolysis following electrical injury. Semin Neurol 1995; 15:329.
  22. Schiff HB, MacSearraigh ET, Kallmeyer JC. Myoglobinuria, rhabdomyolysis and marathon running. Q J Med 1978; 47:463.
  23. Olerud JE, Homer LD, Carroll HW. Incidence of acute exertional rhabdomyolysis. Serum myoglobin and enzyme levels as indicators of muscle injury. Arch Intern Med 1976; 136:692.
  24. Schwaber MJ, Liss HP, Steiner I, Brezis M. Hazard of sauna use after strenuous exercise. Ann Intern Med 1994; 120:441.
  25. Bouchama A, Knochel JP. Heat stroke. N Engl J Med 2002; 346:1978.
  26. Knochel JP. Environmental heat illness. An eclectic review. Arch Intern Med 1974; 133:841.
  27. Sherry P. Sickle cell trait and rhabdomyolysis: case report and review of the literature. Mil Med 1990; 155:59.
  28. Rosenthal MA, Parker DJ. Collapse of a young athlete. Ann Emerg Med 1992; 21:1493.
  29. Knochel JP. Exertional rhabdomyolysis. N Engl J Med 1972; 287:927.
  30. Knochel JP. Neuromuscular manifestations of electrolyte disorders. Am J Med 1982; 72:521.
  31. Knochel JP, Schlein EM. On the mechanism of rhabdomyolysis in potassium depletion. J Clin Invest 1972; 51:1750.
  32. Edwards G, Dora KA, Gardener MJ, et al. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396:269.
  33. Lonka L, Pedersen RS. Fatal rhabdomyolysis in marathon runner. Lancet 1987; 1:857.
  34. Ginsberg MD, Hertzman M, Schmidt-Nowara WW. Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. A syndrome resembling heatstroke. Ann Intern Med 1970; 73:81.
  35. Tein I, DiMauro S, DeVivo DC. Recurrent childhood myoglobinuria. Adv Pediatr 1990; 37:77.
  36. Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27:181.
  37. Felig P, Wahren J. Fuel homeostasis in exercise. N Engl J Med 1975; 293:1078.
  38. Chinnery PF, Johnson MA, Taylor RW, et al. A novel mitochondrial tRNA phenylalanine mutation presenting with acute rhabdomyolysis. Ann Neurol 1997; 41:408.
  39. Eiser AR, Neff MS, Slifkin RF. Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome. Arch Intern Med 1982; 142:601.
  40. Bonnor R, Siddiqui M, Ahuja TS. Rhabdomyolysis associated with near-drowning. Am J Med Sci 1999; 318:201.
  41. Curry SC, Chang D, Connor D. Drug- and toxin-induced rhabdomyolysis. Ann Emerg Med 1989; 18:1068.
  42. Prendergast BD, George CF. Drug-induced rhabdomyolysis--mechanisms and management. Postgrad Med J 1993; 69:333.
  43. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119:400.
  44. Kiernan TJ, Rochford M, McDermott JH. Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism. Int J Cardiol 2007; 119:374.
  45. Gupta S, Blaivas M, Ike RW, Crofford LJ. Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases. J Clin Rheumatol 2001; 7:332.
  46. Scroggie DA, Harris M, Sakai L. Rhabdomyolysis associated with nutritional supplement use. J Clin Rheumatol 2000; 6:328.
  47. Dehoney S, Wellein M. Rhabdomyolysis associated with the nutritional supplement Hydroxycut. Am J Health Syst Pharm 2009; 66:142.
  48. Hohenberger P, Haier J, Schlag PM. Rhabdomyolysis and renal function impairment after isolated limb perfusion--comparison between the effects of perfusion with rhTNF alpha and a 'triple-drug' regimen. Eur J Cancer 1997; 33:596.
  49. Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14:224.
  50. Sitprija V, Gopalakrishnakone P. Snake bite, rhabdomyolysis, and renal failure. Am J Kidney Dis 1998; 31:l.
  51. Isbister GK, Hooper MR, Dowsett R, et al. Collett's snake (Pseudechis colletti) envenoming in snake handlers. QJM 2006; 99:109.
  52. George P, Pawar B, Calton N, Mathew P. Wasp sting: an unusual fatal outcome. Saudi J Kidney Dis Transpl 2008; 19:969.
  53. Betten DP, Richardson WH, Tong TC, Clark RF. Massive honey bee envenomation-induced rhabdomyolysis in an adolescent. Pediatrics 2006; 117:231.
  54. Bedry R, Baudrimont I, Deffieux G, et al. Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med 2001; 345:798.
  55. Lee PT, Wu ML, Tsai WJ, et al. Rhabdomyolysis: an unusual feature with mushroom poisoning. Am J Kidney Dis 2001; 38:E17.
  56. Diaz JH. Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings. Crit Care Med 2005; 33:419.
  57. Saviuc P, Danel V. New syndromes in mushroom poisoning. Toxicol Rev 2006; 25:199.
  58. Zhang B, Yang G, Yu X, et al. Haff disease after eating crayfish in east China. Intern Med 2012; 51:487.
  59. Huang X, Li Y, Huang Q, et al. A past Haff disease outbreak associated with eating freshwater pomfret in South China. BMC Public Health 2013; 13:447.
  60. Centers for Disease Control and Prevention (CDC). Haff disease associated with eating buffalo fish--United States, 1997. MMWR Morb Mortal Wkly Rep 1998; 47:1091.
  61. Paul V, Shamah S, Garankina O, et al. Rhabdomyolysis after fish consumption: Haff's disease. QJM 2014; 107:67.
  62. Pesik NT, Otten EJ. Severe rhabdomyolysis following a viral illness: a case report and review of the literature. J Emerg Med 1996; 14:425.
  63. O'Connor JV, Iyer SK. Myoglobinuria associated with parainfluenza type 2 infection. N Y State J Med 1982; 82:1469.
  64. Ueda K, Robbins DA, Iitaka K, Linnemann CC Jr. Fatal rhabdomyolysis associated with parainfluenza type 3 infection. Hiroshima J Med Sci 1978; 27:99.
  65. Sertogullarindan B, Ozbay MB, Ertem FU, et al. Rhabdomyolysis associated with Mycoplasma pneumoniae infection. Pol Arch Med Wewn 2013; 123:66.
  66. Khan FY, Sayed H. Rhabdomyolysis associated with Mycoplasma pneumoniae pneumonia. Hong Kong Med J 2012; 18:247.
  67. Oishi T, Narita M, Ohya H, et al. Rhabdomyolysis associated with antimicrobial drug-resistant Mycoplasma pneumoniae. Emerg Infect Dis 2012; 18:849.
  68. Armstrong JH. Tropical pyomyositis and myoglobinuria. Arch Intern Med 1978; 138:1145.
  69. Posner MR, Caudill MA, Brass R, Ellis E. Legionnaires' disease associated with rhabdomyolysis and myoglobinuria. Arch Intern Med 1980; 140:848.
  70. Naschitz JE, Yeshurun D, Shagrawi I. Rhabdomyolysis in pneumococcal sepsis. Am J Med 1989; 87:479.
  71. Bachhuber R, Parker RA, Bennett WM. Acute renal failure in toxic shock syndrome owing to rhabdomyolysis. Ann Clin Lab Sci 1983; 13:25.
  72. McKenna UG, Meadows JA 3rd, Brewer NS, et al. Toxic shock syndrome, a newly recognized disease entity. Report of 11 cases. Mayo Clin Proc 1980; 55:663.
  73. Heller HM, Telford SR 3rd, Branda JA. Case records of the Massachusetts General Hospital. Case 10-2005. A 73-year-old man with weakness and pain in the legs. N Engl J Med 2005; 352:1358.
  74. Knochel JP, Moore GE. Rhabdomyolysis in Malaria. N Engl J Med 1993; 329:1206.
  75. Shintani S, Shiigai T, Tsukagoshi H. Marked hypokalemic rhabdomyolysis with myoglobinuria due to diuretic treatment. Eur Neurol 1991; 31:396.
  76. Dominic JA, Koch M, Guthrie GP Jr, Galla JH. Primary aldosteronism presenting as myoglobinuric acute renal failure. Arch Intern Med 1978; 138:1433.
  77. Singhal PC, Kumar A, Desroches L, et al. Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia. Am J Med 1992; 92:458.
  78. Knochel JP. Hypophosphatemia and rhabdomyolysis. Am J Med 1992; 92:455.
  79. Singhal PC, Abramovici M, Venkatesan J. Rhabdomyolysis in the hyperosmolal state. Am J Med 1990; 88:9.
  80. Wang LM, Tsai ST, Ho LT, et al. Rhabdomyolysis in diabetic emergencies. Diabetes Res Clin Pract 1994; 26:209.
  81. Casteels K, Beckers D, Wouters C, Van Geet C. Rhabdomyolysis in diabetic ketoacidosis. Pediatr Diabetes 2003; 4:29.
  82. Akmal M. Rhabdomyolysis in a patient with hypocalcemia due to hypoparathyroidism. Am J Nephrol 1993; 13:61.
  83. Cronin RE. Psychogenic polydipsia with hyponatremia: report of eleven cases. Am J Kidney Dis 1987; 9:410.
  84. Putterman C, Levy L, Rubinger D. Transient exercise-induced water intoxication and rhabdomyolysis. Am J Kidney Dis 1993; 21:206.
  85. Abramovici MI, Singhal PC, Trachtman H. Hypernatremia and rhabdomyolysis. J Med 1992; 23:17.
  86. Denman JP. Hypernatraemia and rhabdomyolysis. Med J Aust 2007; 187:527.
  87. Bennett WR, Huston DP. Rhabdomyolysis in thyroid storm. Am J Med 1984; 77:733.
  88. Shemin D, Cohn PS, Zipin SB. Pheochromocytoma presenting as rhabdomyolysis and acute myoglobinuric renal failure. Arch Intern Med 1990; 150:2384.
  89. Caccamo DV, Keene CY, Durham J, Peven D. Fulminant rhabdomyolysis in a patient with dermatomyositis. Neurology 1993; 43:844.
  90. Pirovino M, Neff MS, Sharon E. Myoglobinuria and acute renal failure with acute polymyositis. N Y State J Med 1979; 79:764.
  91. Kim HW, Choi JR, Jang SJ, et al. Recurrent rhabdomyolysis and myoglobinuric acute renal failure in a patient with polymyositis. Nephrol Dial Transplant 2005; 20:2255.
  92. Barrett SA, Mourani S, Villareal CA, et al. Rhabdomyolysis associated with status asthmaticus. Crit Care Med 1993; 21:151.
  93. Ramsay DA, Zochodne DW, Robertson DM, et al. A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neuropathol Exp Neurol 1993; 52:387.
  94. Dolberg-Stolik OC, Putterman C, Rubinow A, et al. Idiopathic capillary leak syndrome complicated by massive rhabdomyolysis. Chest 1993; 104:123.
  95. Balcarek P, Frosch KH, Quintel M, Stürmer KM. [Systemic capillary leak syndrome causes a compartment syndrome of both lower legs and a forearm. A case report with a review of the literature]. Unfallchirurg 2005; 108:770, 772.
  96. Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002; 83:735.
  97. Mohammed I, Hussain A. Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump: a case report. BMC Clin Pharmacol 2004; 4:6.
Topic 16414 Version 9.0

Topic Outline

GRAPHICS

RELATED TOPICS

All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.